Cognition Therapeutics Inc.

CGTX Nasdaq SEC CIK 1455365
Follow Cognition Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$4.1M +15.9% vs same quarter last year
EPS, diluted −$0.04 +33.3% vs same quarter last year
Operating cash flow −$3.3M +42.3% vs same quarter last year
Operating income −$7.4M −15.7% vs same quarter last year
Net income by quarter
−$7.8M
−$8.5M
−$6.7M
−$4.9M
−$3.3M
−$4.6M
−$3.9M
−$4.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$23.5M
FY24−$34M
FY23−$25.8M
FY22−$21.4M
FY21−$11.7M
FY20−$7.8M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$28.5M
FY23−$16.2M
FY22−$18.7M
FY21−$3.7M
FY20−$3.4M
FY19-